Mixed infections and heteroresistance of Helicobacter pylori contribute to decreased efficacy of treatments. This study aimed to investigate frequency of clarithromycin heteroresistance and its link with mixed infections, medication history, and disease severity. A total of 40 pairs of H. pylori strains were isolated from the antrum and corpus of 97 patients. Susceptibility of the strains to clarithromycin was measured by agar dilution method. Site-specific mutations of 23S rRNA at A2143G, A2142G, and A2142C positions were analyzed by PCR and genomic relatedness of pairs of the strains was determined by random amplified polymorphic DNA (RAPD)-PCR. The results showed a prevalence of 35% (14/40) clarithromycin resistance. Diversity of the antrum and corpus isolates in resistance to clarithromycin was detected among 17.5% (7/40) of the patients. Similarly, diversity in MIC value was also detected in two patients infected with the sensitive strains. Significant difference in frequency of resistance was detected among patients with peptic ulcer disease (PUD) (MIC90 32 μg/mL) and severe gastritis (MIC90 16 μg/mL), compared with those who suffered from non-ulcer dyspepsia (NUD) (MIC90 8 μg/mL) and chronic gastritis (MIC90 0.25 μg/mL). MIC values showed 8-32 folds increased levels in the corpus. A2142G, A2143G, and A2142C mutations were detected in three, two, and two patients, respectively, but not observed in 46% of the resistant strains. RAPD-PCR fingerprints showed identical molecular patterns for the isolates of the corpus and antrum in each patient. In conclusion, microevolution of H. pylori strains during chronic infection, rather than mixed infection, and inappropriate medication appear to be main reasons of treatment failure in adults.

Foodborne and Waterborne Diseases Research Center Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran

Gastroenterology and Liver Diseases Research Center Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran

See more in PubMed

J Clin Microbiol. 2002 Jan;40(1):259-61 PubMed

Nat Rev Cancer. 2002 Jan;2(1):28-37 PubMed

Helicobacter. 2002 Dec;7(6):378-83 PubMed

Helicobacter. 2003 Jun;8(3):202-6 PubMed

BMC Microbiol. 2005 May 25;5:32 PubMed

Appl Environ Microbiol. 2006 Jul;72(7):4713-6 PubMed

Int J Antimicrob Agents. 2007 Sep;30(3):250-4 PubMed

Malays J Pathol. 2009 Jun;31(1):29-34 PubMed

J Clin Microbiol. 2010 Oct;48(10):3703-7 PubMed

Int J Med Sci. 2011 Jan 08;8(1):56-67 PubMed

Microb Drug Resist. 2011 Jun;17(2):149-55 PubMed

Annu Rev Microbiol. 2011;65:329-48 PubMed

Helicobacter. 2012 Apr;17(2):86-95 PubMed

Infect Genet Evol. 2014 Apr;23:196-202 PubMed

World J Gastroenterol. 2014 May 21;20(19):5903-11 PubMed

PLoS One. 2014 Jul 08;9(7):e101481 PubMed

Gut. 2015 May;64(5):720-30 PubMed

Microb Drug Resist. 2015 Feb;21(1):105-10 PubMed

World J Gastroenterol. 2014 Nov 21;20(43):16245-51 PubMed

Jpn J Infect Dis. 2015;68(3):176-80 PubMed

Iran J Basic Med Sci. 2015 Jan;18(1):2-7 PubMed

Front Mol Biosci. 2014 Oct 24;1:19 PubMed

Middle East J Dig Dis. 2015 Apr;7(2):75-81 PubMed

Gastroenterol Hepatol Bed Bench. 2015 Spring;8(Suppl 1):S1-5 PubMed

Gastroenterol Clin North Am. 2015 Sep;44(3):625-38 PubMed

Helicobacter. 2015 Sep;20 Suppl 1:8-16 PubMed

Aliment Pharmacol Ther. 2016 Feb;43(4):514-33 PubMed

Helicobacter. 2016 Oct;21(5):349-63 PubMed

Middle East J Dig Dis. 2016 Jan;8(1):51-6 PubMed

Medicine (Baltimore). 2016 Feb;95(8):e2831 PubMed

Biomed J. 2016 Feb;39(1):14-23 PubMed

Microb Drug Resist. 2017 Apr;23(3):351-358 PubMed

Arq Gastroenterol. 2016 Oct-Dec;53(4):215-223 PubMed

Therap Adv Gastroenterol. 2016 Nov;9(6):836-844 PubMed

PLoS Pathog. 2017 Jan 19;13(1):e1006118 PubMed

Front Cell Infect Microbiol. 2017 May 05;7:168 PubMed

Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis